Demand for Menopause Hormone Therapy Is on the Rise – but Training Gaps Remain for Doctors

Why It Matters

The shortage signals a market gap for manufacturers, while education deficits risk suboptimal care, making enhanced training and research essential to meet rising patient demand.

Key Takeaways

• Demand for menopause hormone therapy (MHT) rising, causing supply shortages
• New Zealand’s Pharmac temporarily rationed MHT due to high demand
• Training gaps persist: 40% UK med schools lack mandatory menopause education
• Lack of research on perimenopause and modern MHT regimens limits guidance
• Online training courses launched to upskill NZ clinicians on menopause care

Pulse Analysis

The resurgence of menopause hormone therapy reflects a broader cultural shift toward proactive midlife health. Long‑term follow‑up of the Women’s Health Initiative and newer transdermal studies have dispelled earlier safety fears, positioning body‑identical estradiol patches and progesterone capsules as preferred options for hot flashes, sleep disturbances, and bone preservation. This scientific confidence, combined with more open conversations about menopause, has spurred a notable uptick in prescriptions, enough to strain supply chains and force New Zealand’s Pharmac to ration medications—a clear indicator of unmet demand.

Yet the prescription boom collides with a persistent education vacuum. Surveys reveal that roughly four in ten UK medical schools omit mandatory menopause curricula, and many U.S. obstetrics‑gynecology residencies lack dedicated modules. Consequently, a generation of clinicians enters practice without the nuanced knowledge needed to counsel patients, tailor dosing, or manage risks such as breast cancer. The knowledge gap translates into delayed diagnoses, patient frustration, and inconsistent care standards, especially in regions like New Zealand where cultural considerations and family dynamics add complexity to treatment decisions.

For the pharmaceutical and health‑service sectors, these dynamics create both challenges and opportunities. Manufacturers must secure reliable production pipelines to avoid future rationing, while investors can watch for firms that prioritize supply resilience and innovative delivery formats. Simultaneously, the push for localized research—particularly on perimenopausal populations and modern MHT formulations—offers a fertile ground for academic‑industry collaborations. Educational initiatives, such as the newly launched online menopause‑care course for New Zealand clinicians, exemplify how targeted upskilling can bridge the gap, improve patient outcomes, and sustain market growth. Aligning policy, research, and training will be pivotal in turning rising demand into a well‑served, evidence‑based segment of women’s health.